{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:28:28Z","timestamp":1776162508704,"version":"3.50.1"},"reference-count":54,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Cardiovascular disease (CVD) prevention guidelines define targets for lifestyle and risk factors for patients at high risk of developing CVD. We assessed the control of these factors, as well as CVD risk perception in patients enrolled into the primary care arm of the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE V) survey in Lithuania. Materials and Methods: Data were collected as the part of the EUROASPIRE V survey, a multicenter, prospective, cross-sectional observational study. Adults without a documented CVD who had been prescribed antihypertensive medicines and\/or lipid-lowering medicines and\/or treatment for diabetes (diet and\/oral antidiabetic medicines and\/or insulin) were eligible for the survey. Data were collected through the review of medical records, patients\u2019 interview, physical examination and laboratory tests. Results: A total of 201 patients were enrolled. Very few patients reached targets for low-density lipoprotein cholesterol (LDL-C) (4.5%), waist circumference (17.4%) and body mass index (15.4%). Only 31% of very high CVD risk patients and 52% of high-risk patients used statins. Blood pressure target was achieved by 115 (57.2%) patients. Only 21.7% of patients at very high actual CVD risk and 27% patients at high risk correctly estimated their risk. Of patients at moderate actual CVD risk, 37.5% patients accurately self-assessed the risk. About 60%\u201380% of patients reported efforts to reduce the intake of sugar, salt or alcohol; more than 70% of patients were current nonsmokers. Only a third of patients reported weight reduction efforts (33.3%) or regular physical activity (27.4%). Conclusions: The control of cardiovascular risk factors in a selected group of primary prevention patients was unsatisfactory, especially in terms of LDL-C level and body weight parameters. Many patients did not accurately perceive their own risk of developing CVD.<\/jats:p>","DOI":"10.3390\/medicina56030134","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T03:54:14Z","timestamp":1584590054000},"page":"134","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Primary Prevention of Cardiovascular Risk in Lithuania\u2014Results from EUROASPIRE V Survey"],"prefix":"10.3390","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4697-5562","authenticated-orcid":false,"given":"Gediminas","family":"Urbonas","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Vencevi\u010dien\u0117","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Clinic of Internal Diseases, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonas","family":"Valius","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ieva","family":"Krivickien\u0117","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linas","family":"Petrauskas","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gintar\u0117","family":"Lazarenkien\u0117","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justina","family":"Karpavi\u010dien\u0117","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Medical Academy, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel\u0117","family":"Bried\u0117","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Clinic of Internal Diseases, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil\u0117","family":"\u017du\u010denkien\u0117","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Clinic of Internal Diseases, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolis","family":"Vencevi\u010dius","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Clinic of Internal Diseases, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrcardio.2014.26","article-title":"Epidemiological studies of CHD and the evolution of preventive cardiology","volume":"11","author":"Wong","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: Epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Di Girolamo, C., Nusselder, W.J., Bopp, M., Bronnum-Hansen, H., Costa, G., Kovacs, K., Leinsalu, M., Martikainen, P., Pacelli, B., and Rubio Valverde, J. (2019). Progress in reducing inequalities in cardiovascular disease mortality in Europe. Heart.","DOI":"10.1136\/heartjnl-2019-315129"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrcardio.2015.82","article-title":"Contributions of risk factors and medical care to cardiovascular mortality trends","volume":"12","author":"Ezzati","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L., Reith, C., Bhala, N., Peto, R., Barnes, E., and Keech, A. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sabatine, M.S., Wiviott, S.D., Im, K., Murphy, S.A., and Giugliano, R.P. (2018). Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels. JAMA Cardiol., 3.","DOI":"10.1001\/jamacardio.2018.2258"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials","volume":"336","author":"Turnbull","year":"2008","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"i721","DOI":"10.1136\/bmj.i721","article-title":"Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: Population based observational study","volume":"352","author":"Jousilahti","year":"2016","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/CRD.0b013e3181a7b34c","article-title":"Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes","volume":"17","author":"Weiss","year":"2009","journal-title":"Cardiol. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.290.7.947","article-title":"Major risk factors for cardiovascular disease: Debunking the \u201conly 50%\u201d myth","volume":"290","author":"Canto","year":"2003","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"NCEP Expert Panel (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106, 3143\u20133421.","DOI":"10.1161\/circ.106.25.3143"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J. Am. Coll Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/DMSO.S13860","article-title":"Lifestyle modification in the management of the metabolic syndrome: Achievements and challenges","volume":"3","author":"Calugi","year":"2010","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/sj.ijo.0802215","article-title":"Updated review on the benefits of weight loss","volume":"26","author":"Vidal","year":"2002","journal-title":"Int. J. Obes. Relat. Metab."},{"key":"ref_19","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein","year":"1992","journal-title":"Int. J. Obes. Relat. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.21037\/cdt.2017.04.06","article-title":"The EUROASPIRE surveys: Lessons learned in cardiovascular disease prevention","volume":"7","author":"Kotseva","year":"2017","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., Chapman, M.J., De Backer, G.G., Delgado, V., and Ference, B.A. (2019). 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J.","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J. Hypertens."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Aguilar-Palacio, I., Malo, S., Feja, C., Lallana, M., Leon-Latre, M., Casasnovas, J.A., Rabanaque, M., and Guallar, E. (2018). Risk factors control for primary prevention of cardiovascular disease in men: Evidence from the Aragon Workers Health Study (AWHS). PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193541"},{"key":"ref_24","first-page":"2098","article-title":"Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study","volume":"32","author":"Banegas","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Blom, D.J., Santos, R.D., Daclin, V., Mercier, F., Ruiz, A.J., Danchin, N., and ICLPS Study Group (2019). The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study. Eur. J. Prev. Cardiol.","DOI":"10.1177\/2047487319871735"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/clc.22955","article-title":"Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy","volume":"41","author":"Figliuzzi","year":"2018","journal-title":"Clin. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2019.03.017","article-title":"Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy","volume":"285","author":"Presta","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_29","unstructured":"(2005). Lietuvos Respublikos Sveikatos apsaugos ministro \u012fsakymas V-913, D\u0117l Asmen\u0173, Priskirtin\u0173 \u0160irdies ir Kraujagysli\u0173 Lig\u0173 Didel\u0117s Rizikos Grupei, Atrankos ir Prevencijos Priemoni\u0173 Finansavimo Programos Patvirtinimo."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Taylor, F., Huffman, M.D., Macedo, A.F., Moore, T.H., Burke, M., Davey Smith, G., Ward, K., and Ebrahim, S. (2013). Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004816.pub5"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamacardio.2016.0218","article-title":"Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews","volume":"1","author":"Karmali","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Halcox, J.P., Banegas, J.R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K.M., and Borghi, C. (2017). Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc. Disord., 17.","DOI":"10.1186\/s12872-017-0591-5"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Halcox, J.P., Tubach, F., Lopez-Garcia, E., De Backer, G., Borghi, C., Dallongeville, J., Guallar, E., Medina, J., Perk, J., and Sazova, O. (2015). Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0115270"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.3399\/bjgp15X686113","article-title":"Statin prescribing for primary prevention of cardiovascular disease: A cross-sectional, observational study","volume":"65","author":"Homer","year":"2015","journal-title":"Br. J. Gen. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ueda, P., Lung, T.W., Lu, Y., Salomon, J.A., Rahimi, K., Clarke, P., and Danaei, G. (2018). Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190688"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/vhrm.2006.2.4.507","article-title":"Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients\u2019 risk level","volume":"2","author":"Roccatagliata","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Turner, G.M., Calvert, M., Feltham, M.G., Ryan, R., Fitzmaurice, D., Cheng, K.K., and Marshall, T. (2016). Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002169"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1177\/2047487316667784","article-title":"Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e023085","DOI":"10.1136\/bmjopen-2018-023085","article-title":"Statins for the primary prevention of cardiovascular disease: An overview of systematic reviews","volume":"9","author":"Byrne","year":"2019","journal-title":"BMJ Open"},{"key":"ref_40","first-page":"684","article-title":"A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care","volume":"53","author":"Kedward","year":"2003","journal-title":"Br. J. Gen. Pract."},{"key":"ref_41","first-page":"805","article-title":"Adherence to lipid-lowering treatment: The patient perspective","volume":"6","author":"Casula","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Fung, V., Graetz, I., Reed, M., and Jaffe, M.G. (2018). Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191817"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.3399\/bjgp18X696365","article-title":"Patient beliefs and attitudes to taking statins: Systematic review of qualitative studies","volume":"68","author":"Ju","year":"2018","journal-title":"Br. J. Gen. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"i3305","DOI":"10.1136\/bmj.i3305","article-title":"Discontinuation and restarting in patients on statin treatment: Prospective open cohort study using a primary care database","volume":"353","author":"Vinogradova","year":"2016","journal-title":"BMJ"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hope, H.F., Binkley, G.M., Fenton, S., Kitas, G.D., Verstappen, S.M.M., and Symmons, D.P.M. (2019). Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0201196"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Naderi, S.H., Bestwick, J.P., and Wald, D.S. (2012). Adherence to drugs that prevent cardiovascular disease: Meta-analysis on 376,162 patients. Am. J. Med., 125.","DOI":"10.1016\/j.amjmed.2011.12.013"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e025587","DOI":"10.1136\/bmjopen-2018-025587","article-title":"Patients\u2019 and health professionals\u2019 attitudes and perceptions towards the initiation of preventive drugs for primary prevention of cardiovascular disease: Protocol for a systematic review of qualitative studies","volume":"9","author":"Qadi","year":"2019","journal-title":"BMJ Open"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Brawarsky, P., Eibensteiner, K., Klinger, E.V., Baer, H.J., Getty, G., Orav, E.J., Colditz, G., and Haas, J.S. (2018). Accuracy of self-perceived risk for common conditions. Cogent Med., 5.","DOI":"10.1080\/2331205X.2018.1463894"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/clc.22841","article-title":"Association between clinical factors and self-underestimation of cardiovascular risk in subjects submitted to a routine health evaluation","volume":"41","author":"Helou","year":"2018","journal-title":"Clin. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/HJR.0b013e32832d194d","article-title":"Perception of cardiovascular risk and comparison with actual cardiovascular risk","volume":"16","author":"Alwan","year":"2009","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/2047487314543074","article-title":"Calculated and perceived cardiovascular risk in asymptomatic subjects submitted to a routine medical evaluation: The perception gap","volume":"22","author":"Katz","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/PRBM.S198280","article-title":"The relationship between psychological states and health perception in individuals at risk for cardiovascular disease","volume":"12","author":"Lee","year":"2019","journal-title":"Psychol. Res. Behav. Manag."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e012063","DOI":"10.1136\/bmjopen-2016-012063","article-title":"Comparison of self-perceived cardiovascular disease risk among smokers with Framingham and PROCAM scores: A cross-sectional analysis of baseline data from a randomised controlled trial","volume":"7","author":"Desgraz","year":"2017","journal-title":"BMJ Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.amjcard.2014.04.006","article-title":"Perceived lifetime risk for cardiovascular disease (from the Dallas Heart Study)","volume":"114","author":"Petr","year":"2014","journal-title":"Am. J. Cardiol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/3\/134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:07:51Z","timestamp":1760173671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/3\/134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["medicina56030134"],"URL":"https:\/\/doi.org\/10.3390\/medicina56030134","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,18]]}}}